Verrica Pharmaceuticals Inc. (VRCA)
Largest Insider Buys in Sector
VRCA Stock Price History Chart
VRCA Stock Performance
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration …
Insider Activity of Verrica Pharmaceuticals Inc.
Over the last 12 months, insiders at Verrica Pharmaceuticals Inc. have bought $12.5M and sold $1.08M worth of Verrica Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Verrica Pharmaceuticals Inc. have bought $8.07M and sold $1.11M worth of stock each year.
Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC (10 percent owner) — $187.55M.
The last purchase of 115,774 shares for transaction amount of $838,204 was made by PERCEPTIVE ADVISORS LLC (10 percent owner) on 2023‑12‑29.
List of Insider Buy and Sell Transactions, Verrica Pharmaceuticals Inc.
| 2024-08-27 | Sale | PRESIDENT AND CEO | 9,021 0.0211% | $2.46 | $22,192 | -38.21% | ||
| 2024-08-27 | Sale | CHIEF LEGAL OFFICER | 9,530 0.0223% | $2.46 | $23,444 | -38.21% | ||
| 2024-08-27 | Sale | Chief Medical Officer | 3,601 0.0084% | $2.46 | $8,858 | -38.21% | ||
| 2024-08-27 | Sale | CHIEF COMMERCIAL OFFICER | 8,993 0.0211% | $2.46 | $22,123 | -38.21% | ||
| 2024-08-27 | Sale | CHIEF FINANCIAL OFFICER | 7,899 0.0185% | $2.46 | $19,432 | -38.21% | ||
| 2024-08-26 | Sale | PRESIDENT AND CEO | 24,979 0.0606% | $2.66 | $66,444 | -40.47% | ||
| 2024-08-26 | Sale | CHIEF LEGAL OFFICER | 26,183 0.0635% | $2.66 | $69,647 | -40.47% | ||
| 2024-08-26 | Sale | Chief Medical Officer | 9,888 0.024% | $2.66 | $26,302 | -40.47% | ||
| 2024-08-26 | Sale | CHIEF COMMERCIAL OFFICER | 24,709 0.0599% | $2.66 | $65,726 | -40.47% | ||
| 2024-08-26 | Sale | CHIEF FINANCIAL OFFICER | 21,820 0.0529% | $2.66 | $58,041 | -40.47% | ||
| 2024-07-23 | Sale | PRESIDENT AND CEO | 154 0.0003% | $6.98 | $1,075 | +1.86% | ||
| 2024-07-23 | Sale | CHIEF LEGAL OFFICER | 91 0.0002% | $6.98 | $635 | +1.86% | ||
| 2024-07-23 | Sale | Chief Medical Officer | 86 0.0002% | $6.98 | $600 | +1.86% | ||
| 2024-07-23 | Sale | CHIEF COMMERCIAL OFFICER | 115 0.0003% | $6.98 | $803 | +1.86% | ||
| 2024-07-22 | Sale | PRESIDENT AND CEO | 32,469 0.0765% | $7.06 | $229,231 | -74.08% | ||
| 2024-07-22 | Sale | CHIEF LEGAL OFFICER | 21,649 0.051% | $7.06 | $152,842 | -74.08% | ||
| 2024-07-22 | Sale | Chief Medical Officer | 18,421 0.0434% | $7.06 | $130,052 | -74.08% | ||
| 2024-07-22 | Sale | CHIEF COMMERCIAL OFFICER | 25,461 0.06% | $7.06 | $179,755 | -74.08% | ||
| 2023-12-29 | 10 percent owner | 115,774 0.2752% | $7.24 | $838,204 | -21.72% | |||
| 2023-12-28 | 10 percent owner | 126,116 0.2934% | $7.08 | $892,901 | -22.67% |
Insider Historical Profitability
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 7099182 15.5681% | $0.89 | 10 | 0 | <0.0001% |
| White Ted | PRESIDENT AND CEO | 215967 0.4736% | $0.89 | 7 | 7 | +0.47% |
| Hayes Christopher G. | CHIEF LEGAL OFFICER | 105773 0.232% | $0.89 | 3 | 7 | +53.25% |
| Goldenberg Gary | Chief Medical Officer | 94261 0.2067% | $0.89 | 1 | 7 | +61.6% |
| Bonaccorso Joe | CHIEF COMMERCIAL OFFICER | 73114 0.1603% | $0.89 | 1 | 7 | <0.0001% |
Institutional Investor Ownership
| Perceptive Advisors | $42.03M | 16.74 | 7.1M | 0% | +$0 | 0.03 | |
| Avoro Capital Advisors Llc | $23.68M | 9.43 | 4M | 0% | +$0 | 0.28 | |
| Fidelity Investments | $8.93M | 3.56 | 1.51M | +0.01% | +$1,101.12 | <0.01 | |
| The Vanguard Group | $7.51M | 2.99 | 1.27M | +0.6% | +$45,045.28 | <0.0001 | |
| BlackRock | $6.6M | 2.63 | 1.11M | -1.91% | -$128,363.38 | <0.0001 |